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Commentary
Ethics and Economics of the COVID-19
Pandemic in the United States
Peter Hilsenrath1 , and Tyrone Borders2
Abstract
The Covid-19 experience provides a natural experiment in personal and social ethics. Difficult decisions are routinely made to
optimize lives and livelihoods. This commentary provides background and insight into the ethical and economic foundations
underpinning dilemmas of this historic pandemic.
Keywords
COVID 19, economics, ethics, philosophy, policy, utilitarianism, Kant, pandemic, public health, quality-adjusted life year
Introduction
The COVID 19 epidemic is a watershed event. It has exposed
severe weaknesses in public health preparedness and govern-
ance. It also underscores social ills such as disparities and
inadequate safety nets. These shortcomings are generally
widely understood. Less obvious and perhaps more consequen-
tial are the philosophical and ethical responses we observe in
the United States and elsewhere. What are the rights of indi-
viduals to social protection from the virus? And what are the
rights of economic participants to their livelihoods in the face
of this biological threat? A common refrain is that there is no
tradeoff, that what is best for public health is best for the
economy. There is some truth to this. Economies are more
likely to prosper the less the biological threat. But there are
tradeoffs and in practice many decisions are made seeking to
optimize between lives and livelihoods.
On the economic side of the leger unemployment jumped to
near Great Depression levels. Trillions of dollars of economic
welfare were lost to delay infections and boost hospital and
intensive care capacity for the expected surge that did indeed
overwhelm parts of Italy and New York City. Once the curve
turned down, authorities around the world opened economies
instead of extinguishing the epidemic.
In the United States, infection rates have since resurged,
especially in sunbelt states. Authorities are reluctant to reimpose
lockdown conditions. Social patience is a factor. The initial shut-
down to save lives was applauded as noble and perhaps even the
heroic thing to do. But eventually the “heroics” began to look ill-
advised to many and protests emerged to open the economy.
Economies were subsequently partially opened with a tradeoff:
willingness to accept some level of infection and fatality rates for
the greater good of the economy and social welfare.
Philosophers have debated ethics for thousands of years.
Many of our public health, medical and economic experts hold
the Ph.D. That stands for Doctor of Philosophy. One would
expect widespread discourse on what the current crisis tells
us about our ethics instead of the dearth of reflection in the
academic literature and the media. One way to evaluate this
issue is to view relevant perspectives from the standpoint of
two schools: the first is the utilitarian school identified with the
19th-century political economist John Stuart Mill and founda-
tional for mainstream business and economics. It emphasizes
the greatest utility or happiness for the population subject to
basic human rights. A pragmatism and emphasis on maximiz-
ing social welfare is part of this perspective. The second
focuses on rights and duties of the individual. This school is
identified with the 18th-century German philosopher Imma-
nuel Kant. It emphasizes the dignity of individual humans and
the obligation to respect rights of others. Both philosophical
perspectives have antecedents in antiquity. The Epicureans
provide foundation for utilitarianism and some argue Stoicism
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underpins Kant and deontological ethics. Deontological ethics
posits moral right and wrong regardless of consequence. It
emphasizes duties and rights of the individual.
Philosophy and Economics
Putting a price on life is anathema for politicians and society
more broadly. We shun such decisions. Yet widespread open-
ing of the economy with implicit acceptance of additional fatal-
ities makes for such a decision. There are limits to the
economic burden societies are willing to bear for health. This
is consistent with use of cost per quality-adjusted life-year
criteria to allocate scarce resources to and within the health
sector. Health economists have increasingly used such tools
over the last several decades. And even the World Health Orga-
nization, recognizing the importance of efficient resource allo-
cation, recommends thresholds for cost per quality-adjusted
life year, or its cousin, cost per disability-adjusted life year.1
Utilitarians, even those who strongly support human rights, can
argue that the greater interests of society are best served by
drawing a line, accepting a certain level of morbidity and mor-
tality, and allowing the economy to move forward. Those more
concerned with absolute rights of the individual from social
harm are uneasy with our collective choices.
The obfuscation of tradeoffs between health and economic
welfare does not serve a clear-thinking society confident of its
ethical foundations. It is time for cost-effectiveness analysis to
be more widely embraced, understood and discussed for deci-
sions related to epidemics, such as COVID 19, or more routine
coverage decisions such as for Medicare. This will advance
transparency and better frame decision making considering the
utilitarian impulse to optimize social welfare, even at signifi-
cant human cost. Realistic thresholds must be identified.
A prominently cited University of Chicago study concluded
that lockdowns were efficient using an $11.5-million threshold
for the age-adjusted statistical value of human life.2 This was
derived from willingness to pay studies that are notoriously
inconsistent and sometimes inadmissible in court. Such thresh-
olds seem high to many. They may work for relatively rare
occurrences. But dislocating millions of dollars per afflicted
person for an event that could directly affect many millions
of people over a short period of time is more problematic. The
total cost is measured in trillions of dollars.
Research has improved to better identify mortality associ-
ated with COVID 19. In the United States, the case-fatality rate
is under 4 percent. But the infection-fatality rate is much lower
because of unidentified cases. This rate is estimated at approx-
imately 0.6 percent, albeit with considerable variation by age
and other socioeconomic factors.3 Consider what would occur
were there no public health response to the virus. Perhaps
70 percent of the population would become infected.4 This
implies about 232 million infections and 1,392,000 deaths. But
an estimated 295,000 people are projected to have died anyway
by December 1st 2020, suggesting public measures will save
no more than approximately 1.1 million lives.5 The Congres-
sional Budget Office (CBO) estimated that the COVID
response will incur a cumulative economic cost of 7.9 trillion
dollars.6 This works out to $7.2 million a life saved (unad-
justed). The University of Chicago study concluded public
health measures to prevent COVID were worth $8 trillion. The
CBO cost estimate falls within the Chicago study limits of
being worthwhile, but not by much. Minor changes in assump-
tions could easily lead to the conclusion that our public health
distancing measures are not worthwhile.
Historians, with the benefit of hindsight, will look back on
this episode and better pass judgment on the wisdom of our
decisions. It is incumbent for an honest, rational and deliberate
society to address such crises in a sober and informed manner.
Let us hope that next time we can be more judicious about
how best to improve pandemic public health measures with
both costs and benefits in clear view. More targeted use of the
most cost-effective measures is essential for optimization
between lives and livelihoods. We can surely generate more
output with less morbidity and mortality. Authorities can start
with clear guidance about masks, therapies such as hydroxy-
chloroquine, and other sources of confused messaging.7 And
when choices must be made, explicit information concerning
tradeoffs about how much the utilitarian greater good should
triumph over the unfortunate minority is vital for the next
pandemic.
Public health and medical experts tend to focus on health
outcomes, such as mortality rates, while ignoring economic
costs. One explanation for this one-sided focus lies in the lack
of emphasis on health economics in traditional health profes-
sional training programs. Public health schools sometimes
offer elective courses on health economics that introduce
cost-effectiveness, but like medical schools they do not require
that all students be exposed to key health economics concepts.
Going forward, health professional education would benefit
from curriculum reforms that include coursework about how
to assess the economic benefits as well as the costs of health-
related policies including for pandemic events. This will help
ease discord between health and business communities. It will
also underscore the dilemma between utilitarian objectives and
the sanctity of human life.
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